Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FQJX6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,773
Award facts
- Contract value 100% obligated
- $34,772.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $34,772.94 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injector units. The contract, issued on January 30, 2026, with an ultimate completion date of February 2, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance capability within the federal pharmaceutical supply chain, with its PPV-G GEN V prime contract—valued at $499,999,999 and extending through December 31, 2036—authorizing DLA to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription medications, biologics, vaccines, and medical consumables. The vendor's extensive product portfolio and consistent contract performance across multiple therapeutic categories, combined with its established relationships with the Defense Logistics Agency's Medical Supply Chain division, position it as a critical supplier supporting military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQJX6?
SPE2DR26FQJX6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FQJX6 worth?
The government has obligated $34,773 on SPE2DR26FQJX6.
Is contract SPE2DR26FQJX6 an order under another contract?
Yes. SPE2DR26FQJX6 is a delivery order under SPE2DR25D9135, an indefinite delivery contract.
Was contract SPE2DR26FQJX6 competed?
The extent of competition for SPE2DR26FQJX6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award